Senti Biosciences (SNTI) Revenue & Revenue Breakdown
Senti Biosciences Revenue Highlights
Latest Revenue (Y)
$2.56M
Main Segment (Y)
License
Senti Biosciences Revenue by Period
Senti Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.56M | -40.25% |
| 2022-12-31 | $4.29M | 87.08% |
| 2021-12-31 | $2.29M | 481.47% |
| 2020-12-31 | $394.00K | 363.53% |
| 2019-12-31 | $85.00K | - |
Senti Biosciences generated $2.56M in revenue during NA 2023, up -40.25% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Senti Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $333.00K | 30.59% |
| 2023-09-30 | $255.00K | -72.79% |
| 2023-06-30 | $937.00K | -9.56% |
| 2023-03-31 | $1.04M | 1655.93% |
| 2022-12-31 | $59.00K | -76.40% |
| 2022-09-30 | $250.00K | -77.44% |
| 2022-06-30 | $1.11M | 29.74% |
| 2022-03-31 | $854.00K | 57.27% |
| 2021-12-31 | $543.00K | -41.36% |
| 2021-09-30 | $926.00K | 19.02% |
| 2021-06-30 | $778.00K | 980.56% |
| 2021-03-31 | $72.00K | 3500.00% |
| 2020-12-31 | $2.00K | - |
Senti Biosciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Senti Biosciences Revenue Breakdown
Senti Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 |
|---|---|
| License | $800.00K |
Senti Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 22: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 23 | Mar 23 |
|---|---|---|
| License | $200.00K | $400.00K |
Senti Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: License (100.00%).
Senti Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| LIPO | Lipella Pharmaceuticals | $449.62M | $136.43M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| SNTI | Senti Biosciences | $2.56M | - |
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| BLCM | Bellicum Pharmaceuticals | $1.50M | $1.00M |
| RAPT | RAPT Therapeutics | - | - |
| CNTB | Connect Biopharma | - | - |
| CING | Cingulate | - | - |
| HILS | Tharimmune | - | - |
| CVKD | Cadrenal Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| TYRA | Tyra Biosciences | - | - |
| XLO | Xilio Therapeutics | - | $2.36M |
SNTI Revenue FAQ
What is Senti Biosciences’s yearly revenue?
Senti Biosciences's yearly revenue for 2023 was $2.56M, representing a decrease of -40.25% compared to 2022. The company's yearly revenue for 2022 was $4.29M, representing an increase of 87.08% compared to 2021. SNTI's yearly revenue for 2021 was $2.29M, representing an increase of 481.47% compared to 2020.
What is Senti Biosciences’s quarterly revenue?
Senti Biosciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). SNTI's quarterly revenue for Q4 2023 was $333K, a 30.59% increase from the previous quarter (Q3 2023), and a 464.41% increase year-over-year (Q4 2022).
What is Senti Biosciences’s revenue growth rate?
Senti Biosciences's revenue growth rate for the last 3 years (2021-2023) was 11.79%, and for the last 5 years (2019-2023) was 2912.94%.
What are Senti Biosciences’s revenue streams?
Senti Biosciences's revenue streams in c 22 are License
What is Senti Biosciences’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Senti Biosciences was License. This segment made a revenue of $800K, representing 100.00% of the company's total revenue.